Therapeutic Candidate or Device
Novel testing of a cell based therapy (Mesenchymal Stromal Cells) for respiratory failure from ARDS.
COVID-19 positive or negative ARDS patients
It will hopefully improve oxygenation in ARDS patients and potentially decrease mortality.
Unmet Medical Need
There is an unmet need for more effective treatments for ARDS both COVID-19 positive and COVID-19 negative.
Improvement in respiratory function after ARDS
Major Proposed Activities
Assess clinical efficacy of MSC treatment for ARDS in this double-blind, randomized, placebo-controlled trial.
This new therapy could improve survival from ARDS, a major cause of acute respiratory failure in the citizens of California.